Non–Small Cell Lung Cancer, Version 6.2015

The National Comprehensive Cancer Network

McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+ · Cited by 16,760 · see citing works

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works

First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190 · see citing works

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873 · see citing works

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581 · see citing works

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574 · see citing works

<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers

Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555 · see citing works

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495 · see citing works

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280 · see citing works

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Camidge, D. R., Bang, Y., Kwak, E. L., Iafrate, A. J., Varella‐Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S. I., Kim, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,271 · see citing works

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897 · see citing works

Management of non-small-cell lung cancer: recent developments

Reck, M., Heigener, D. F., Mok, T. S. K., Soria, J., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714 · see citing works

Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population

Rodig, S. J., Mino-Kenudson, M. A., Đačić, S., Yeap, B. Y., Shaw, A. T., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N. I., Mark, E. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 677 · see citing works

Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers

Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639 · see citing works

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636 · see citing works

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610 · see citing works

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 595 · see citing works

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · see citing works

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Li, T., Kung, H., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 515 · see citing works

<i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473 · see citing works

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

Drilon, A. E. D. C., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P. J., Ross, J. S., Miller, V. A., Ginsberg, M. S., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 467 · see citing works

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Mino-Kenudson, M. A., Chirieac, L. R., Law, K., Hornick, J. L., Lindeman, N. I., Mark, E. J., Cohen, D., Johnson, B. E., Janne, P. A., Iafrate, A. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2845 · Cited by 424 · see citing works

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., Wang, D., Li, Q., Qin, S., Hu, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70355-3 · Cited by 422 · see citing works

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

Dias-Santagata, D. C., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J. E., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 392 · see citing works

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlési, F., Filleron, T., Dingemans, A. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 367 · see citing works

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360 · see citing works

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 358 · see citing works

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 349 · see citing works

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

Camidge, D. R., Kono, S. A., Flacco, A., Tan, A. C., Doebele, R. C., Zhou, Q. H., Crinò, L., Franklin, W. A., & Varella‐Garcia, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0851 · Cited by 341 · see citing works

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304 · see citing works

Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

D’Angelo, S. P., Pietanza, M. C., Johnson, M. L., Riely, G. J., Miller, V. A., Sima, C. S., Zakowski, M. F., Rusch, V. W., Ladanyi, M., & Kris, M. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6181 · Cited by 301 · see citing works

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300 · see citing works

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 300 · see citing works

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

Leighl, N. B., Rekhtman, N., Biermann, W. A., Huang, J., Mino-Kenudson, M., Ramalingam, S. S., West, H., Whitlock, S., & Somerfield, M. R. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3055 · Cited by 281 · see citing works

Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

Han, S., Kim, T., Jeon, Y. K., Hwang, P. G., Im, S., Lee, K.-H., Kim, J. H., Kim, D., Heo, D. S., Kim, N. K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2845 · Cited by 250 · see citing works

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M. C., Paz-Ares, L. G., Reck, M., Smit, E. F., Syrigos, K., Stahel, R. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 244 · see citing works

Clinical next‐generation sequencing in patients with non–small cell lung cancer

Hagemann, I. S., Devarakonda, S. H. K., Lockwood, C. M., Spencer, D. H., Guebert, K., Bredemeyer, A. J., Al‐Kateb, H., Nguyen, T. T., Duncavage, E. J., Cottrell, C. E., et al. (2014) · Cancer · doi:10.1002/cncr.29089 · Cited by 232 · see citing works

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W. J., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230 · see citing works

KRAS Mutation: Should We Test for It, and Does It Matter?

Roberts, P. J., & Stinchcombe, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0454 · Cited by 228 · see citing works

Recent Clinical Advances in Lung Cancer Management

Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 221 · see citing works

Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

Pao, W. J., & Ladanyi, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1387 · Cited by 214 · see citing works

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

Thunnissen, E., Bubendorf, L., Dietel, M., Elmberger, G., Kerr, K. M., López‐Ríos, F., Moch, H., Olszewski, W. T., Pauwels, P., Penault-Llorca, F. M., et al. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1281-4 · Cited by 212 · see citing works

EGFR testing in lung cancer is ready for prime time

Hirsch, F. R., & Bunn, P. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70110-x · Cited by 198 · see citing works

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators

Wynes, M. W., Sholl, L. M., Dietel, M., Schuuring, E. M. D., Tsao, M., Yatabe, Y., Tubbs, R. R., & Hirsch, F. R. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000115 · Cited by 164 · see citing works

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression

Kim, H., Yoo, S.-B., Choe, J., Paik, J. H., Xu, X., Nitta, H., Zhang, W., Grogan, T. M., Lee, C., Jheon, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821cfc73 · Cited by 162 · see citing works

Computed Tomography Screening for Lung Cancer: Has It Finally Arrived? Implications of the National Lung Screening Trial

Aberle, D. R., Abtin, F. G., & Brown, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3110 · Cited by 159 · see citing works

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

Gazdar, A. F., Robinson, L. D., Oliver, D., Xing, C., Travis, W. D., Soh, J., Toyooka, S., Watumull, L. M., Xie, Y., Kernstine, K. H., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000130 · Cited by 156 · see citing works

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

Onitsuka, T., Uramoto, H., Nose, N., Takenoyama, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.022 · Cited by 142 · see citing works

Lung Cancer Screening, Version 1.2015

Wood, D. E., Kazerooni, E. A., Baum, S. L., Dransfield, M. T., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D. M., Klippenstein, D. L., Kumar, R., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0006 · Cited by 137 · see citing works

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

Oxnard, G. R., Miller, V. A., Robson, M. E., Azzoli, C. G., Pao, W. J., Ladanyi, M., & Arcila, M. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318250ed9d · Cited by 128 · see citing works

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the L ung C ancer M utation C onsortium

Villaruz, L. C., Socinski, M. A., Abberbock, S. R., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., et al. (2014) · Cancer · doi:10.1002/cncr.29042 · Cited by 125 · see citing works

Crizotinib and Testing for ALK

Shaw, A. T., Solomon, B. J., & Kenudson, M. M. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0115 · Cited by 123 · see citing works

Targeted therapy for non-small-cell lung cancer: past, present and future

Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 121 · see citing works

ALK Status Testing in Non–Small Cell Lung Carcinoma

Minca, E. C., Portier, B. P., Wang, Z., Lanigan, C. P., Farver, C. F., Feng, Y., Ma, P. C., Arrossi, V., Pennell, N. A., & Tubbs, R. R. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.01.004 · Cited by 121 · see citing works

EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 116 · see citing works

The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112 · see citing works

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

Atherly, A. J., & Camidge, D. R. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.60 · Cited by 104 · see citing works

Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma

Peters, S., Michielin, O. A., & Zimmermann, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6143 · Cited by 104 · see citing works

ALK Rearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment

Alì, G., Proietti, A., Pelliccioni, S., Niccoli, C., Lupi, C., Sensi, E., Giannini, R., Borrelli, N., Menghi, M., Chella, A., et al. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0388-oa · Cited by 86 · see citing works

Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer

Weickhardt, A. J., Aisner, D. L., Franklin, W. A., Varella‐Garcia, M., Doebele, R. C., & Camidge, D. R. (2012) · Cancer · doi:10.1002/cncr.27913 · Cited by 85 · see citing works

Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort

Yu, H. A., Arcila, M. E., Fleischut, M. H., Stadler, Z. K., Ladanyi, M., Berger, M. F., Robson, M. E., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000052 · Cited by 82 · see citing works

Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria

von Laffert, M., Warth, A., Penzel, R., Schirmacher, P., Kerr, K. M., Elmberger, G., Schildhaus, H., Büttner, R., López‐Ríos, F., Reu, S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000332 · Cited by 76 · see citing works

NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.

Ettinger, D. S., Cox, J. D., Ginsberg, R. J., Komaki, R. U., Kris, M. G., Livingston, R. B., & Sugarbaker, D. J. (1996) · PubMed · Cited by 71 · see citing works

Ten Years of Progress in Non–Small Cell Lung Cancer

Ettinger, D. S. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0029 · Cited by 63 · see citing works

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations

Lund‐Iversen, M., Kleinberg, L., Fjellbirkeland, L., Helland, Å., & Brustugun, O. T. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182614a9d · Cited by 62 · see citing works

EGFR Assays in Lung Cancer

Đačić, S. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31817bf5a9 · Cited by 53 · see citing works

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

Zhou, J., Zhao, J., Sun, K., Wang, B., Wang, L., Chen, X., Zheng, J., You, Q., Wang, X., Ding, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092828 · Cited by 48 · see citing works

Identification of driver mutations in lung cancer: first step in personalized cancer

Planchard, D. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0263-z · Cited by 37 · see citing works

Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma

Shepherd, F. A., & Tsao, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3996 · Cited by 28 · see citing works

The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence

Weickhardt, A. J., & Camidge, D. R. (2011) · Clinical Investigation · doi:10.4155/cli.11.92 · Cited by 22 · see citing works

Molecular profiling of lung cancer

Minárik, M. (2016) · Onkologie · doi:10.36290/xon.2016.003 · Cited by 16 · see citing works

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

Chun, S. G., Hu, C., Choy, H., Komaki, R. U., Timmerman, R. D., Schild, S. E., Bogart, J. A., Dobelbower, M. C., Bosch, W. R., Galvin, J. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1378 · Cited by 747 · see citing works

The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics

Cheng, T. D., Cramb, S. M., Baade, P. D., Youlden, D. R., Nwogu, C. E., & Reid, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.021 · Cited by 601 · see citing works

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 591 · see citing works

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325 · see citing works

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery

Chang, J. Y., Mehran, R. J., Feng, L., Verma, V., Liao, Z. X., Welsh, J. W., Lin, S. H., O’Reilly, M. S., Jeter, M. D., Balter, P. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00401-0 · Cited by 322 · see citing works

Specific Gut Microbiome Signature Predicts the Early-Stage Lung Cancer

Zheng, Y., Fang, Z., Xue, Y., Zhang, J., Zhu, J., Gao, R., Yao, S., Ye, Y., Wang, S., Lin, C., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1737487 · Cited by 301 · see citing works

hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma

Zhu, X., Wang, X., Wei, S., Chen, Y., Chen, Y., Fan, X., Han, S., & Wu, G. (2017) · FEBS Journal · doi:10.1111/febs.14132 · Cited by 295 · see citing works

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Wu, Y.-L. L. C., Cheng, Y., Zhou, J., Lü, S., Zhang, Y., Zhao, J., Kim, D., Soo, R. A., Kim, S., Pan, H., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30154-5 · Cited by 257 · see citing works

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Gutierrez, M. E., Choi, K., Lanman, R. B., Licitra, E. J., Skrzypczak, S. M., Benito, R. P., Wu, T., Arunajadai, S. G., Kaur, S., Harper, H. D., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.004 · Cited by 206 · see citing works

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11

Fleur, L. L., Falk-Sörqvist, E., Smeds, P., Berglund, A., Sundström, M., Mattsson, J. S., Brandén, E., Koyi, H., Isaksson, J., Brunnström, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.003 · Cited by 202 · see citing works

Bevacizumab: A Review of Its Use in Advanced Cancer

Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 180 · see citing works

Prognostic effect of liver metastasis in lung cancer patients with distant metastasis

Ren, Y., Dai, C., Zheng, H. W., Zhou, F., She, Y., Jiang, G., Fei, K., Yang, P., Xie, D., & Chen, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10644 · Cited by 163 · see citing works

Uncommon EGFR mutations in advanced non-small cell lung cancer

O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 152 · see citing works

Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment

Mattonen, S. A., Palma, D. A., Johnson, C., Louie, A. V., Landis, M. S., Rodrigues, G., Chan, I. Y. M., Etemad‐Rezai, R., Yeung, T. P. C., Senan, S., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.12.369 · Cited by 141 · see citing works

PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway

Zhan, P., Zhang, B., Xi, G., Wu, Y., Liu, H., Liu, Y.-F., Xu, W., Zhu, Q., Cai, F., Zhou, Z., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0682-z · Cited by 140 · see citing works

Emerging landscape of circular RNAs in lung cancer

Hu, W., Bi, Z., Chen, Z., Liu, C., Li, L., Zhang, F., Zhou, Q. Y., Zhu, W., Song, Y., Zhan, B.-T., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.006 · Cited by 134 · see citing works

Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway

Tao, L., Huang, G., Wang, R., Pan, Y., He, Z., Chu, X., Song, H., & Chen, L. (2016) · Scientific Reports · doi:10.1038/srep38408 · Cited by 131 · see citing works

EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

Gallant, J., Sheehan, J. H., Shaver, T. M., Bailey, M., Lipson, D., Chandramohan, R., Brewer, M. R., York, S. J., Kris, M. G., Pietenpol, J. A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0654 · Cited by 128 · see citing works

National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer

Higgins, K. A., O’Connell, K., Liu, Y., Gillespie, T. W., McDonald, M. W., Pillai, R. N., Patel, K. R., Patel, P. R., Robinson, C. G., Simone, C. B., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.10.001 · Cited by 123 · see citing works

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study

Yamamoto, N., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Yamanaka, T., Tanaka, M., Takahashi, K., & Fukuoka, M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.020 · Cited by 123 · see citing works

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer

Vantaku, V., Dong, J., Ambati, C. R., Perera, D. N., Donepudi, S. R., Amara, C. S., Putluri, V., Ravi, S. S., Robertson, M. J., Piyarathna, D. W. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1515 · Cited by 116 · see citing works

SBI0206965, a novel inhibitor of Ulk1, suppresses non-small cell lung cancer cell growth by modulating both autophagy and apoptosis pathways

Tang, F., Hu, P., Yang, Z., Xue, C. H., Gong, J., Sun, S., Liu, S., Zhang, S., Li, Z., Yang, C., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5635 · Cited by 115 · see citing works

Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 112 · see citing works

Targeting HER2 in the treatment of non-small cell lung cancer

Mar, N., Vredenburgh, J. J., & Wasser, J. S. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.018 · Cited by 102 · see citing works

Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma

Qian, F., Yang, W., Wang, R., Xu, J., Wang, S., Zhang, Y., Jin, B., Yu, K., & Han, B. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.09.143 · Cited by 101 · see citing works

Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis

Sabatini, L. M., Mathews, C., Ptak, D. M., Doshi, S., Tynan, K., Hegde, M., Burke, T. L., & Bossler, A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.010 · Cited by 96 · see citing works

Stereotactic body radiotherapy for oligoprogressive cancer

Cheung, P. (2016) · British Journal of Radiology · doi:10.1259/bjr.20160251 · Cited by 95 · see citing works

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?

Mino-Kenudson, M. A., & Mino-Kenudson, M. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0009 · Cited by 93 · see citing works

Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes

Chen, H., Yao, W., Chu, Q., Han, R., Wang, Y., Sun, J., Wang, D., Wang, Y., Cao, M., & He, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.024 · Cited by 93 · see citing works

Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer

Verma, V., Simone, C. B., Allen, P. K., Gajjar, S., Shah, C., Zhen, W. K., Harkenrider, M. M., Hallemeier, C. L., Jabbour, S. K., Matthiesen, C. L., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.10.041 · Cited by 93 · see citing works

Site‐to‐Site Reproducibility and Spatial Resolution in MALDI–MSI of Peptides from Formalin‐Fixed Paraffin‐Embedded Samples

Ly, A., Longuespée, R., Casadonte, R., Wandernoth, P., Schwamborn, K., Bollwein, C., Marsching, C., Kriegsmann, K., Hopf, C., Weichert, W., et al. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800029 · Cited by 92 · see citing works

Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens

Kriegsmann, M., Casadonte, R., Kriegsmann, J., Dienemann, H., Schirmacher, P., Kobarg, J. H., Schwamborn, K., Stenzinger, A., Warth, A., & Weichert, W. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.057513 · Cited by 90 · see citing works

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma

Yang, C. J., Wang, H., Kumar, A., Wang, X., Hartwig, M. G., D’Amico, T. A., & Berry, M. F. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.07.032 · Cited by 89 · see citing works

Long-term outcomes after lobectomy for non–small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis

Yang, C. J., Kumar, A., Gulack, B. C., Mulvihill, M. S., Hartwig, M. G., Wang, X., D’Amico, T. A., & Berry, M. F. (2015) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2015.12.028 · Cited by 84 · see citing works

CircRNA has_circ_0001946 promotes cell growth in lung adenocarcinoma by regulating miR-135a-5p/SIRT1 axis and activating Wnt/β-catenin signaling pathway

Yao, Y., Hua, Q., Zhou, Y., & Shen, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.120 · Cited by 82 · see citing works

Circular RNA hsa_circ_0000326 acts as a miR-338-3p sponge to facilitate lung adenocarcinoma progression

Xu, Y., Yu, J., Huang, Z., Fu, B., Tao, Y., Qi, X., Mou, Y., Hu, Y., Wang, Y., Cao, Y., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01556-4 · Cited by 80 · see citing works

miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor

Qin, Q., Wei, F., Zhang, J., Wang, X.-W., & Li, B. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12889 · Cited by 76 · see citing works

Phase IB Trial of the Anti‐Cancer Stem Cell DLL4‐Binding Agent Demcizumab with Pemetrexed and Carboplatin as First‐Line Treatment of Metastatic Non‐Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0543-0 · Cited by 74 · see citing works

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Kim, S. T., Banks, K. C., Lee, S., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 72 · see citing works

The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells

Hu, S., Li, X., Xu, R., Ye, L., Kong, H., Zeng, X., Wang, H., & Xie, W. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw026 · Cited by 71 · see citing works

Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies

Fisher, K. E., Zhang, L., Wang, J., Smith, G. H., Newman, S., Schneider, T. M., Pillai, R. N., Kudchadkar, R. R., Owonikoko, T. K., Ramalingam, S. S., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.006 · Cited by 71 · see citing works

Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival

Berry, M. F., Gao, R. W., Kunder, C. A., Backhus, L. M., Khuong, A., Kadoch, M. A., Leung, A. N. C., & Shrager, J. B. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.020 · Cited by 71 · see citing works

Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features

Khorrami, M., Jain, P., Bera, K., Alilou, M., Thawani, R., Patil, P. D., Ahmad, U., Murthy, S. C., Stephans, K. L., Fu, P., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.020 · Cited by 71 · see citing works

TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib

Wang, W., Xu, C., Chen, Y., Liu, W., Zhong, L., Chen, F., Zhuang, W., Huang, Y., Huang, Z., Chen, R., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.98 · Cited by 70 · see citing works

p62-Induced Cancer-Associated Fibroblast Activation via the Nrf2-ATF6 Pathway Promotes Lung Tumorigenesis

Kang, J. I., Kim, D. H., Sung, K. W., Shim, S. M., Cha‐Molstad, H., Soung, N., Lee, K. H., Hwang, J., Lee, H. G., Kwon, Y. T., et al. (2021) · Cancers · doi:10.3390/cancers13040864 · Cited by 70 · see citing works

Three Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting NSCLC

Tang, Q., Ni, Z., Cheng, Z., Xu, J., Yu, H., & Yin, P. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430226 · Cited by 69 · see citing works

The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer

Zhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 65 · see citing works

Circ-SOX4 drives the tumorigenesis and development of lung adenocarcinoma via sponging miR-1270 and modulating PLAGL2 to activate WNT signaling pathway

Gao, N., & Ye, B. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1065-x · Cited by 65 · see citing works

HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma

Wang, Z., TANG, F., Hu, P., Wang, Y., Gong, J., Sun, S., & Xie, C. (2016) · Oncology Reports · doi:10.3892/or.2016.4811 · Cited by 65 · see citing works

Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells

Zhao, Q., Mao, A., YAN, J., Sun, C., Di, C., Zhou, X. H., Li, H., Guo, R., & Zhang, H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3301 · Cited by 61 · see citing works

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer

Yerokun, B. A., Yang, C. J., Gulack, B. C., Li, X., Mulvihill, M. S., Gu, L., Wang, X., Harpole, D. H., D’Amico, T. A., Berry, M. F., et al. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.02.065 · Cited by 61 · see citing works

Surgical treatment for early stage non-small cell lung cancer

Raman, V., Yang, C. J., Deng, J. Z., & D’Amico, T. A. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.172 · Cited by 59 · see citing works

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy

Verstegen, N. E., Lagerwaard, F. J., Hashemi, S. M. S., Dahele, M. R., Slotman, B. J., & Senan, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000576 · Cited by 58 · see citing works

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.005 · Cited by 54 · see citing works

A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis

Wang, Y., Zhang, Q., Gao, Z., Shan, X., Zhao, Y., Zhang, K., Shi, R., & Bao, X. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0822-1 · Cited by 54 · see citing works

Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy

Leeman, J. E., Rimner, A., Montecalvo, J., Hsu, M., Zhang, Z., von Reibnitz, D., Panchoo, K., Yorke, E. D., Adusumilli, P. S., Travis, W. D., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.09.037 · Cited by 54 · see citing works

Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis

Yang, C. J., Gu, L., Shah, S. A., Yerokun, B. A., D’Amico, T. A., Hartwig, M. G., & Berry, M. F. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.021 · Cited by 54 · see citing works

Overexpression of PEAK1 contributes to epithelial–mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling

Ding, C., Tang, W., Fan, X., Wang, X., Wu, H., Xu, H., Xu, W., Gao, W., & Wu, G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0817-1 · Cited by 54 · see citing works

Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives

Chen, H., Zhang, T., Wu, Q., Huang, X., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.664290 · Cited by 52 · see citing works

Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF)

Li, R., Yu, L., Lin, S., Wang, L., Dong, X., Yu, L., Li, W., & Li, B. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0698-3 · Cited by 52 · see citing works

Surgical quality of wedge resection affects overall survival in patients with early stage non–small cell lung cancer

Ajmani, G. S., Wang, C., Kim, K. W., Howington, J. A., & Krantz, S. B. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.02.095 · Cited by 52 · see citing works

MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

Zheng, J., Xu, T., Chen, F., & Zhang, Y. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-018-0552-z · Cited by 52 · see citing works

Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation

Binkley, M. S., Hiniker, S. M., Chaudhuri, A. A., Maxim, P. G., Diehn, M., Loo, B. W., & Shultz, D. B. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.12.007 · Cited by 51 · see citing works

The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection

Billatos, E. S., Vick, J. L., Lenburg, M. E., & Spira, A. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3187 · Cited by 51 · see citing works

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review

Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 52 · see citing works

Uniportal video-assisted thoracoscopic surgery: safety, efficacy and learning curve during the first 250 cases in Quebec, Canada

Drevet, G., & Ugalde, P. A. (2016) · Annals of Cardiothoracic Surgery · doi:10.21037/acs.2016.03.05 · Cited by 50 · see citing works

Mcl‐1 targeting could be an intriguing perspective to cure cancer

BLASIO, A. D., Vento, R., & Fiore, R. D. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26786 · Cited by 50 · see citing works

Pulmonary Sarcomatoid Carcinoma: Experience From SEER Database and Shanghai Pulmonary Hospital

Sun, L., Dai, J., Chen, Y., Duan, L., He, W., Chen, Q., Wang, H., Zhu, Y., Zhang, H., Jiang, G., et al. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.02.071 · Cited by 50 · see citing works

Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study

You, D., Wang, D., Wu, Y., Chen, X., Shao, F., Wei, Y., Zhang, R., Lange, T., Ma, H., Xu, H., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02400-6 · Cited by 49 · see citing works

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial

Guberina, M., Eberhardt, W., Stuschke, M., Gauler, T. C., Heinzelmann, F., Cheufou, D. H., Kimmich, M., Friedel, G., Schmidberger, H., Darwiche, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx069 · Cited by 49 · see citing works

Identification of Circulating Long Noncoding RNA Linc00152 as a Novel Biomarker for Diagnosis and Monitoring of Non-Small-Cell Lung Cancer

Li, N., Feng, X., Tan, Q., Luo, P., Wei, J., Zhu, M., Liang, C., Tu, J., & Ning, Y. (2017) · Disease Markers · doi:10.1155/2017/7439698 · Cited by 48 · see citing works

Personalised medicine for nonsmall cell lung cancer

Mascaux, C., Tomasini, P., Greillier, L., & Barlési, F. (2017) · European Respiratory Review · doi:10.1183/16000617.0066-2017 · Cited by 48 · see citing works

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review

Tomasik, B., Skrzypski, M. T., Bieńkowski, M., Dziadziuszko, R., & Jassem, J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-742 · Cited by 45 · see citing works

Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma

Hung, J., Wu, Y., Chou, T., Jeng, W., Yeh, Y., & Hsu, W. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.10.075 · Cited by 46 · see citing works

PIK3CA mutations as prognostic factor in squamous cell lung carcinoma

McGowan, M., Silye, A., Lund‐Iversen, M., Solberg, S. K., Helland, Å., Hirsch, F. R., & Brustugun, O. T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.018 · Cited by 46 · see citing works

Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT

Hörner‐Rieber, J., Bernhardt, D., Blanck, O., Duma, M. N., Eich, H. T., Gerum, S., Gkika, E., Hass, P., Henkenberens, C., Herold, H., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.024 · Cited by 43 · see citing works

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations

Zheng, D., Chen, H., Wang, R., Zhang, Y., Pan, Y., Cheng, X., Cheng, C., Zheng, S., Li, H., Gong, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s96834 · Cited by 44 · see citing works

Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters

Zhou, Z., Folkert, M. R., Cannon, N., Iyengar, P., Westover, K. D., Zhang, Y., Choy, H., Timmerman, R. D., Yan, J., Xie, X.-J., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.04.029 · Cited by 44 · see citing works

Genetic variants in ABCG 1 are associated with survival of nonsmall‐cell lung cancer patients

Wang, Y., Liu, H., Ready, N., Su, L., Wei, Y., Christiani, D. C., & Wei, Q. (2016) · International Journal of Cancer · doi:10.1002/ijc.29991 · Cited by 43 · see citing works

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer

Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43 · see citing works

LncRNA MALAT-1 competitively regulates miR-124 to promote EMT and development of non-small-cell lung cancer

Wu, J., Weng, Y., He, F., Liang, D., & Cai, L. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000626 · Cited by 43 · see citing works

The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer

Geva, S., Rozenblum, A. B., Twito, T., Grinberg, R., Dvir, A., Soussan‐Gutman, L., Ilouze, M., Roisman, L. C., Dudnik, E., Zer, A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.101 · Cited by 43 · see citing works

Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling

Zarif, T. E., Meador, C. B., Qiu, X., Seo, J.-H., Davidsohn, M. P., Savignano, H., Lakshminarayanan, G., McClure, H. M., Canniff, J., Fortunato, B. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0466 · Cited by 42 · see citing works

Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non–Small Cell Lung Cancer and Tuberculosis

Kang, F., Wang, S., Tian, F., Zhao, M., Zhang, M., Wang, Z., Li, G., Liu, C., Yang, W., Li, X., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167924 · Cited by 42 · see citing works

A new tool to predict lung cancer based on risk factors

Ahmad, A. S., & Mayya, A. M. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03402 · Cited by 42 · see citing works

Oncologic Outcomes of Surgery Versus SBRT for Non–Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis

IJsseldijk, M. A., Shoni, M., Siegert, C., Wiering, B., van Engelenburg, A. K. C., Tsai, T. C., ten Broek, R. P. G., & Lebenthal, A. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.04.017 · Cited by 42 · see citing works

Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy

Velez, A., DeMaio, A. J., & Sterman, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203539 · Cited by 43 · see citing works

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB

Luo, J., Huang, Q., Wang, R., Han, B., Zhang, J., Zhao, H., Fang, W., Luo, Q., Yang, J., Yang, Y., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2192-6 · Cited by 41 · see citing works

Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging

Kang, F., Wang, Z., Li, G., Wang, S., Liu, D., Zhang, M., Zhao, M., Yang, W., & Wang, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3696-2 · Cited by 41 · see citing works

Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients

Cui, J., Wang, L., Zhu, T., Gong, W., Zhou, H., Liu, Z., & Yin, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05246-8 · Cited by 41 · see citing works

Lung adenocarcinoma with intraoperatively diagnosed pleural seeding: Is main tumor resection beneficial for prognosis?

Li, C., Kuo, S., Hsu, H., Lin, M., & Chen, J. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.09.162 · Cited by 41 · see citing works

Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: A literature-based meta-analysis of randomized studies

Mörth, C., & Valachis, A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.015 · Cited by 40 · see citing works

Toward Understanding the Antitumor Effects of Water-Soluble Fullerene Derivatives on Lung Cancer Cells: Apoptosis or Autophagy Pathways?

Wong, C., Zhilenkov, A. V., Kraevaya, O. A., Mishchenko, D. V., Troshin, P. A., & Hsu, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00652 · Cited by 40 · see citing works

Computed tomography–guided lung biopsy: a randomized controlled trial of low-dose versus standard-dose protocol

Fu, Y., Li, G., Xu, Q.-S., Shi, Y., Wang, C., & Wang, T. (2019) · European Radiology · doi:10.1007/s00330-019-06464-6 · Cited by 40 · see citing works

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Cox, M. L., Yang, C. J., Speicher, P. J., Anderson, K. L., Fitch, Z. W., Gu, L., Davis, R. P., Wang, X., D’Amico, T. A., Hartwig, M. G., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.003 · Cited by 39 · see citing works

Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers

Horne, Z. D., Richman, A. H., Dohopolski, M. J., Clump, D. A., Burton, S. A., & Heron, D. E. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.014 · Cited by 39 · see citing works

Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer

Park, C., Kim, J.-E., Kim, M., Kho, B., Park, H.-Y., Kim, T.-O., Shin, H., Cho, H.-J., Choi, Y. D., Oh, I., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02944-w · Cited by 39 · see citing works

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective

Rocco, G., Nason, K. S., Brunelli, A., Varela, G., Waddell, T. K., & Jones, D. R. (2016) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.01.035 · Cited by 39 · see citing works

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38 · see citing works

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer

Shen, C., Kehl, K. L., Zhao, B., Simon, G. R., Zhou, S., & Giordano, S. H. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.11.002 · Cited by 38 · see citing works

Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer

Reckamp, K. L. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0046 · Cited by 28 · see citing works

Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment

Aisner, D. L., & Riely, G. J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.5020 · Cited by 39 · see citing works

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation

Vigneswaran, J., Tan, Y. C., Murgu, S. D., Won, B. M., Patton, K. A., Villaflor, V. M., Hoffman, P. C., Hensing, T. A., Hogarth, D. K., Malik, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7739 · Cited by 27 · see citing works

How and when to use genetic markers for nonsmall cell lung cancer

Lazarus, D. R., & Ost, D. E. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328362075c · Cited by 17 · see citing works

Reflex Testing for Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Fluorescence In Situ Hybridization in Non–Small Cell Lung Cancer

Mino-Kenudson, M. A., & Mark, E. J. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2011-0029-rai.1 · Cited by 33 · see citing works